However, the limited experimental design and paucity of strong data ask for more experiments to proof the feasibility of this combination for treating HCC.
2) Despite the expression of cleaved PARP was very low in the tumors treated with TTFields or sorafenib alone ( as shown in IHC-images in Figure 4F), the authors declare about ~ 20% of positive cells, as show in the graphs below IHC-staining. Similar, the graphs illustrating the LC3 expression are not in a proper fit with the images shown in Figure 4D.